title: Nanoparticle-based drug delivery to improve the efficacy of antiretroviral therapy in the central nervous system.
abstract: Antiretroviral drug therapy plays a cornerstone role in the treatment of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome patients. Despite obvious advances over the past 3 decades, new approaches toward improved management of infected individuals are still required. Drug distribution to the central nervous system (CNS) is required in order to limit and control viral infection, but the presence of natural barrier structures, in particular the blood-brain barrier, strongly limits the perfusion of anti-HIV compounds into this anatomical site. Nanotechnology-based approaches may help providing solutions for antiretroviral drug delivery to the CNS by potentially prolonging systemic drug circulation, increasing the crossing and reducing the efflux of active compounds at the blood-brain barrier, and providing cell/tissue-targeting and intracellular drug delivery. After an initial overview on the basic features of HIV infection of the CNS and barriers to active compound delivery to this anatomical site, this review focuses on recent strategies based on antiretroviral drug-loaded solid nanoparticles and drug nanosuspensions for the potential management of HIV infection of the CNS.
authors.affiliation: Instituto de Engenharia Biomédica (INEB), Porto, Portugal.
authors.forename: Maria João
authors.initials: MJ
authors.lastname: Gomes
authors.affiliation: Instituto de Engenharia Biomédica (INEB), Porto, Portugal ; Instituto de Investigação e Formação Avançada em Ciências e Tecnologias da Saúde (IINFACTS), Instituto Superior de Ciências da Saúde-Norte, CESPU, Gandra, Portugal.
authors.forename: José das
authors.initials: Jd
authors.lastname: Neves
authors.affiliation: Instituto de Engenharia Biomédica (INEB), Porto, Portugal ; Instituto de Investigação e Formação Avançada em Ciências e Tecnologias da Saúde (IINFACTS), Instituto Superior de Ciências da Saúde-Norte, CESPU, Gandra, Portugal.
authors.forename: Bruno
authors.initials: B
authors.lastname: Sarmento
mesh_terms: D044966:Anti-Retroviral Agents / Q000008:administration & dosage*; D004339:Drug Compounding / Q000379:methods; D004357:Drug Synergism; D018792:Encephalitis, Viral / Q000628:therapy*; D015658:HIV Infections / Q000628:therapy*; D006801:Humans; D053769:Nanocapsules / Q000737:chemistry / Q000627:therapeutic use* / Q000648:ultrastructure*
chemical_list: D044966:Anti-Retroviral Agents; D053769:Nanocapsules
keywords: HIV/AIDS; blood–brain barrier; drug targeting; efflux transporters; protease inhibitors
references.citation: J Lipid Res. 2001 Jul;42(7):1007-17
references.pmid: 11441126
references.citation: AIDS. 2004 Jan 1;18 Suppl 1:S75-8
references.pmid: 15075501
references.citation: Eur J Pharm Biopharm. 2011 Feb;77(2):265-74
references.pmid: 21118722
references.citation: J Control Release. 2011 Mar 10;150(2):204-11
references.pmid: 21108978
references.citation: AIDS Care. 2009 Nov;21(11):1343-56
references.pmid: 20024710
references.citation: Mol Interv. 2003 Mar;3(2):90-105, 51
references.pmid: 14993430
references.citation: J Antimicrob Chemother. 2012 Jun;67(6):1446-8
references.pmid: 22357802
references.citation: Int J Pharm. 2007 Aug 1;340(1-2):143-52
references.pmid: 17418986
references.citation: Eur J Pharm Biopharm. 2011 Jan;77(1):84-8
references.pmid: 21074612
references.citation: Neurobiol Dis. 2010 Jan;37(1):13-25
references.pmid: 19664713
references.citation: Nat Rev Immunol. 2005 Jan;5(1):69-81
references.pmid: 15630430
references.citation: J Acquir Immune Defic Syndr. 1999 Aug 15;21(5):371-5
references.pmid: 10458617
references.citation: Int J Pharm. 2008 Jan 22;347(1-2):93-101
references.pmid: 17651927
references.citation: Adv Drug Deliv Rev. 2010 Mar 18;62(4-5):458-77
references.pmid: 19914314
references.citation: AIDS. 2011 Jan 28;25(3):357-65
references.pmid: 21124201
references.citation: J Neurovirol. 2011 Feb;17(1):3-16
references.pmid: 21174240
references.citation: Biomaterials. 2008 Nov;29(33):4429-38
references.pmid: 18760470
references.citation: Neurol Clin. 2008 Aug;26(3):799-819, x
references.pmid: 18657727
references.citation: Am J Med. 1988 Aug 29;85(2A):189-94
references.pmid: 3165603
references.citation: Int J Pharm. 2010 Jul 15;394(1-2):115-21
references.pmid: 20433914
references.citation: Methods Mol Biol. 2011;683:3-19
references.pmid: 21053118
references.citation: AIDS Res Hum Retroviruses. 2009 Apr;25(4):457-61
references.pmid: 19320601
references.citation: Eur J Pharm Biopharm. 2002 Sep;54(2):165-70
references.pmid: 12191688
references.citation: Front Biosci. 2004 Sep 01;9:2680-5
references.pmid: 15358591
references.citation: J Cell Biol. 1997 Aug 25;138(4):877-89
references.pmid: 9265653
references.citation: J Infect Dis. 1995 May;171(5):1166-71
references.pmid: 7751691
references.citation: Curr HIV/AIDS Rep. 2011 Mar;8(1):54-61
references.pmid: 21191673
references.citation: Colloids Surf B Biointerfaces. 2012 Feb 1;90:75-82
references.pmid: 22024400
references.citation: Clin Infect Dis. 2005 Dec 15;41(12):1787-93
references.pmid: 16288405
references.citation: Drug Dev Ind Pharm. 2002 Jan;28(1):1-13
references.pmid: 11858519
references.citation: J Drug Target. 2005 Apr;13(3):179-87
references.pmid: 16036306
references.citation: Clin Pharmacokinet. 2001;40(12):893-905
references.pmid: 11735608
references.citation: Biochim Biophys Acta. 2010 Aug;1801(8):806-18
references.pmid: 20170744
references.citation: Nanomedicine (Lond). 2009 Jul;4(5):557-74
references.pmid: 19572821
references.citation: Blood. 2006 Oct 15;108(8):2827-35
references.pmid: 16809617
references.citation: Ann Pharmacother. 1992 May;26(5):660-70
references.pmid: 1350471
references.citation: Top HIV Med. 2010 Apr-May;18(2):45-55
references.pmid: 20516524
references.citation: Acta Pharm. 2008 Mar;58(1):61-74
references.pmid: 18337208
references.citation: World J Gastroenterol. 2006 Jun 7;12(21):3332-7
references.pmid: 16733848
references.citation: Cell Mol Neurobiol. 2000 Feb;20(1):77-95
references.pmid: 10690503
references.citation: Neurobiol Dis. 2010 Jan;37(1):48-57
references.pmid: 19664710
references.citation: J Acquir Immune Defic Syndr. 2004 Jun 1;36(2):649-58
references.pmid: 15167283
references.citation: Int J Nanomedicine. 2012;7:2373-88
references.pmid: 22661891
references.citation: Pharm Res. 2008 Oct;25(10):2262-71
references.pmid: 18516666
references.citation: Colloids Surf B Biointerfaces. 2011 Sep 1;86(2):305-13
references.pmid: 21565469
references.citation: Adv Drug Deliv Rev. 2010 Mar 18;62(4-5):503-17
references.pmid: 19914319
references.citation: Brain Res. 2009 Jul 28;1282:142-55
references.pmid: 19477169
references.citation: Curr HIV Res. 2010 Jul;8(5):396-404
references.pmid: 20426757
references.citation: J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Mar 1;17(3):235-8
references.pmid: 9495223
references.citation: Nanomedicine. 2014 Jan;10(1):177-85
references.pmid: 23845925
references.citation: J Gene Med. 2010 Feb;12(2):219-27
references.pmid: 19950109
references.citation: J Control Release. 2014 Jan 28;174:195-201
references.pmid: 24316476
references.citation: Drug Deliv Transl Res. 2013 Aug 1;3(4):336-51
references.pmid: 23894728
references.citation: Neurosci Lett. 2009 Oct 16;464(1):47-51
references.pmid: 19679165
references.citation: AIDS. 2009 Jan 2;23(1):83-7
references.pmid: 19050389
references.citation: Eur J Pharm Biopharm. 2008 Sep;70(1):75-84
references.pmid: 18472255
references.citation: AAPS J. 2008 Sep;10(3):455-72
references.pmid: 18726697
references.citation: Methods Enzymol. 2012;509:41-60
references.pmid: 22568900
references.citation: Exp Biol Med (Maywood). 2005 Feb;230(2):118-27
references.pmid: 15673560
references.citation: J Infect Dis. 2012 Nov 15;206(10):1577-88
references.pmid: 22811299
references.citation: J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Jan 1;20(1):39-43
references.pmid: 9928728
references.citation: HIV Clin Trials. 2006 May-Jun;7(3):142-53
references.pmid: 16880170
references.citation: Nanomedicine (Lond). 2013 Feb;8(2):223-37
references.pmid: 23173734
references.citation: Science. 2013 Feb 22;339(6122):961-5
references.pmid: 23430655
references.citation: Part Fibre Toxicol. 2010 Mar 03;7:3
references.pmid: 20199661
references.citation: Clin Pharmacokinet. 1998 Mar;34(3):189-201
references.pmid: 9533981
references.citation: AIDS. 2012 Apr 24;26(7):890-3
references.pmid: 22313954
references.citation: J Drug Target. 2007 Jan;15(1):89-98
references.pmid: 17365278
references.citation: Int J Nanomedicine. 2010 Apr 07;5:157-66
references.pmid: 20463931
references.citation: J Neurochem. 2008 Dec;107(6):1518-28
references.pmid: 19094056
references.citation: Antimicrob Agents Chemother. 2012 Apr;56(4):1985-9
references.pmid: 22290964
references.citation: Expert Opin Drug Deliv. 2009 Aug;6(8):771-84
references.pmid: 19566446
references.citation: J Neurovirol. 2007 Jun;13(3):210-24
references.pmid: 17613711
references.citation: Mol Interv. 2010 Oct;10(5):293-304
references.pmid: 21045243
references.citation: Annu Rev Pharmacol Toxicol. 2007;47:323-55
references.pmid: 16961459
references.citation: Nanomedicine (Lond). 2009 Dec;4(8):903-17
references.pmid: 19958227
references.citation: Nanotoxicology. 2011 Dec;5(4):592-605
references.pmid: 21175298
references.citation: Int J Nanomedicine. 2007;2(2):129-41
references.pmid: 17722542
references.citation: J Neuroimmune Pharmacol. 2010 Dec;5(4):592-601
references.pmid: 20237859
references.citation: Virology. 2007 Feb 5;358(1):148-58
references.pmid: 16997345
references.citation: Curr Pharm Des. 2004;10(12):1295-312
references.pmid: 15134482
references.citation: J Acquir Immune Defic Syndr. 2012 Apr 1;59(4):376-81
references.pmid: 22217676
references.citation: Nanomedicine. 2011 Jun;7(3):333-40
references.pmid: 21094278
references.citation: AIDS. 2011 Jul 17;25(11):1437-9
references.pmid: 21712657
references.citation: Nanomedicine (Lond). 2006 Jun;1(1):9-12
references.pmid: 17716203
references.citation: J Immunol. 2009 Jul 1;183(1):661-9
references.pmid: 19535632
references.citation: Drug Discov Today. 2008 Dec;13(23-24):1099-106
references.pmid: 18848640
references.citation: Bioconjug Chem. 2008 Jun;19(6):1179-85
references.pmid: 18473444
references.citation: Drugs. 1998 May;55(5):729-36; discussion 737-8
references.pmid: 9585869
references.citation: Antivir Ther. 2008;13(3):369-74
references.pmid: 18572749
references.citation: J Clin Invest. 1996 Jun 1;97(11):2517-24
references.pmid: 8647944
references.citation: Int J Pharm. 2008 Mar 3;351(1-2):271-81
references.pmid: 17976933
references.citation: Prog Brain Res. 2009;180:225-33
references.pmid: 20302837
references.citation: Int J Nanomedicine. 2012;7:5301-14
references.pmid: 23055735
references.citation: Lancet. 2010 Jul 3;376(9734):49-62
references.pmid: 20609987
references.citation: AIDS. 2012 Nov 13;26(17):2135-44
references.pmid: 22824628
references.citation: AIDS Res Hum Retroviruses. 2011 Aug;27(8):853-62
references.pmid: 21175357
references.citation: Brain Res. 2006 Sep 13;1109(1):1-13
references.pmid: 16857178
references.citation: J Drug Target. 2006 Jan;14(1):45-53
references.pmid: 16603451
references.citation: J Drug Target. 2002 Jun;10(4):317-25
references.pmid: 12164380
references.citation: Expert Opin Drug Deliv. 2013 Jul;10(7):927-55
references.pmid: 23330786
references.citation: Arch Neurol. 2008 Jan;65(1):65-70
references.pmid: 18195140
references.citation: Annu Rev Med. 2002;53:557-93
references.pmid: 11818490
references.citation: PLoS One. 2009 Sep 01;4(9):e6877
references.pmid: 19721718
references.citation: Cell Mol Life Sci. 2008 Oct;65(20):3145-67
references.pmid: 18581055
references.citation: J Control Release. 2012 Dec 28;164(3):364-9
references.pmid: 22732475
references.citation: Nat Rev Drug Discov. 2007 Aug;6(8):650-61
references.pmid: 17667956
references.citation: Int J Pharm. 2011 Dec 15;421(2):341-52
references.pmid: 21986114